Slovenia Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Slovenia Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Slovenia Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Krka's exposure to Eastern European markets will continue to act as a drag on revenue growth. However, strong sales growth in Western Europe will mitigate the impact of revenue declines for the short term. We expect a continued focus on cost containment by European healthcare payers to moderate Krka's growth outlook over the longer term, unless the company looks to geographically diversify its exposure.

Headline Expenditure Projections

  • Pharmaceuticals: EUR675mn (USD896mn) in 2014 to EUR671mn (USD738mn) in 2015; -0.6% in local currency terms and -17.6% in US dollar terms. Forecasts unchanged compared to previous quarter.

  • Healthcare: EUR3.22bn (USD4.27bn) in 2014 to EUR3.23bn (USD3.55bn) in 2015; 0.3% in local currency terms and -16.8% in US dollar terms. Forecasts unchanged compared to previous quarter.

BMI Risk/Reward Index

Slovenia scores 50.4 out of a total of 100 in our Pharmaceutical Risk/Reward Index for Q116 - same score as in the previous quarter. This places the country 11th in our Index of 20 countries and slightly above the average for the region, which is 49.6.

Key Trends And Developments

  • In August, Slovenian generic pharmaceutical company Krka was named among the top three exporters of the country in terms of sales revenue generated overseas, according to a survey by daily Finance. Krka garnered EUR1.09bn (USD1.19bn) in revenues from product sales in foreign markets in 2014, a 2.5% increase compared with 2013. The share of exports in Krka's total revenue reached 95.7% in 2014. Energy companies Gen-I and HSE were also on the top three list, with foreign sales of EUR1.03bn (USD1.13bn) and EUR760mn (USD834mn) in 2014, respectively. The top three exporters are followed by automaker Revoz and another pharmaceutical company Lek.

  • Krka's first half results for 2015 were boosted by strong sales in Germany and other Western European markets, although this was offset by declines in sales within Russia and Ukraine. Krka's exposure to Russia and Ukraine continued to present headwinds to topline growth, owing to the impact of currency depreciation and the volatile economic conditions within both countries. Revenues in H115 were broadly flat y-o-y at EUR600mn (USD672mn) while net profit for Krka rose by 5% y-o-y to EUR112.3mn (USD125.8mn).

  • In September, pharmaceutical company Lek, owned by Swiss multinational Novartis, opened a EUR24m addition to its packaging centre in Lendava on Wednesday with PM Miro Cerar and Swiss President Simonetta Sommaruga attending the ceremony, according to medlines.org. Cerar said the project, which was co-financed with EUR0.5mn in public funds, was an 'excellent' example of cooperation between a foreign investor and local employees. Cerar said he had seen quite a few successful projects during the government visit to the region of Pomurje, which had led him to conclude that the region was reviving.

BMI Economic View

Slovenia's high government debt load and residual problems in the banking sector remain a persistent threat to fiscal stability in Slovenia, although ongoing fiscal consolidation plans should lead to a gradual reduction in public debt/GDP ratios.

BMI Political View

Slovenia is disproportionately exposed to the growing refugee crisis in Europe as the Western Balkan route becomes the most popular route to Europe for refugees arriving in Greece. Despite this, the political outlook for Slovenia remains relatively stable.

Headline Pharmaceuticals & Healthcare Forecasts (Slovenia 2013-2019)
2013 2014 2015f 2016f 2017f 2018f 2019f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 0.933 0.896 0.738 0.726 0.761 0.821 0.890
Pharmaceutical sales, % of GDP 1.94 1.81 1.77 1.73 1.71 1.69 1.68
Pharmaceutical sales, % of health expenditure 21.7 21.0 20.8 20.8 20.9 21.0 21.1
Health spending, USDbn 4.291 4.270 3.551 3.489 3.650 3.911 4.213
BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Slovenia 2013-2019)
8
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovenia 2011-2019)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2011-2019)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2011-2019)
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2011-2019)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovenia 2011-2019)
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovenia 2011-2019)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovenia 2011-2019)
25
OTC Medicines Market Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovenia 2011-2019)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (Slovenia 2013-2019)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovenia 2013-2019)
31
Industry Risk Reward Index
32
Central And Eastern Europe Risk/Reward Index - Q1 2016
32
Slovenia Risk/Reward Index
39
Rewards
39
Risks
39
Regulatory Review
41
Intellectual Property Issues
42
Pricing Regime
42
Reimbursement Regime
44
Market Overview
46
Healthcare Sector
47
Table: Healthcare Resources (Slovenia 2009-2014)
51
Table: Healthcare Personnel (Slovenia 2009-2014)
51
Table: Healthcare Activity (Slovenia 2009-2014)
52
Research & Development
52
Clinical Trials
52
Epidemiology
53
Competitive Landscape
56
Research-Based Industry
56
Table: Table: Multinational Market Activity
56
Generic Drugmakers
57
Pharmaceutical Industry Developments
58
Company Profile
59
Krka
59
Lek (Novartis/Sandoz)
65
Demographic Forecast
69
Table: Population Headline Indicators (Slovenia 1990-2025)
70
Table: Key Population Ratios (Slovenia 1990-2025)
70
Table: Urban/Rural Population & Life Expectancy (Slovenia 1990-2025)
71
Table: Population By Age Group (Slovenia 1990-2025)
71
Table: Population By Age Group % (Slovenia 1990-2025)
72
Glossary
74
Methodology
76
Pharmaceutical Expenditure Forecast Model
76
Healthcare Expenditure Forecast Model
76
Notes On Methodology
77
Risk/Reward Index Methodology
78
Index Overview
79
Table: Pharmaceutical Risk/Reward Index Indicators
79
Indicator Weightings
80

The Slovenia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Slovenia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovenia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Slovenia, to test other views - a key input for successful budgeting and strategic business planning in the Slovenian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Slovenian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Slovenia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.